logo
Plus   Neg
Share
Email

US Military Bars Afghan Airline For Alleged Opium Smuggling: Reports

US military officials has barred Afghanistan's largest private airline, Kam Air, from receiving military contracts, citing allegations of drug smuggling, media reported Friday.

The decision to blacklist Kam Air follows an investigation conducted by the US military, which showed the airline transported large quantities of opium to neighbouring Tajikistan on civilian flights.

US military spokesman Lester Carroll reportedly said, "The commander of Central Command authorised the contracting agencies not to do business with Kam Air based on information that was in the investigation."

Airline owner Zemary Kamgar has firmly rejected the allegations, noting that they were insulting to thorough security checks conducted by Afghan and Tajik forces, and reportedly was consulting with his lawyers over the US move.

Afghan Transport Minister Daud Ali Najafi has also strongly denied the drug smuggling allegations, stating that security checks at Kabul international airport are very tight.

As per reports, Kam Air is the first major Afghan company to be penalized by the US military over drug allegations. Kam Air operates a fleet of some 16 planes, including Boeing 767s and 747s.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT